share_log

HC Wainwright & Co. Downgrades Surface Oncology to Neutral, Announces $5 Price Target

HC Wainwright & Co. Downgrades Surface Oncology to Neutral, Announces $5 Price Target

HC Wainwright & Co.將表面腫瘤學評級下調至中性,宣佈5美元的目標價格
Benzinga ·  2023/06/20 06:09

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Surface Oncology (NASDAQ:SURF) from Buy to Neutral and announces $5 price target.

HC Wainwright & Co. 分析師Swayampakula Ramakanth將表面腫瘤學(納斯達克股票代碼:SURF)的評級從買入下調至中性,並宣佈了5美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論